Novel combination treatment of CDK 4/6 inhibitors with PARP inhibitors in triple negative breast cancer cells
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s00210-022-02375-4.pdf
Reference37 articles.
1. Albakova Z, Siam MKS, Sacitharan PK, Ziganshin RH, Ryazantsev DY, Sapozhnikov AM (2021) Extracellular heat shock proteins and cancer: new perspectives. Transl Oncol 14(2):100995
2. Choo JRE, Lee SC (2018) CDK4–6 inhibitors in breast cancer: current status and future development. Expert Opin Drug Metab Toxicol 14(11):1123–1138
3. Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58(3):621–681
4. Chuang HC, Kapuriya N, Kulp SK, Chen CS, Shapiro CL (2012) Differential anti-proliferative activities of poly (ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells. Breast Cancer Res Treat 134(2):649–659
5. Collins JM, Nordstrom BL, McLaurin KK, Dalvi TB, McCutcheon SC, Bennett JC, Murphy BR, Singhal PK, McCrea C, Shinde R, Briceno JM (2021) A real-world evidence study of CDK4/6 inhibitor treatment patterns and outcomes in metastatic breast cancer by germline BRCA mutation status. Oncol Ther 9(2):575–589
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Impact of Molecular Profiling on Therapy Management in Breast Cancer;Journal of Clinical Medicine;2024-08-23
2. Effects of combined use of ribociclib with PARP1 inhibitor on cell kinetics in breast cancer;Oncology Letters;2024-04-03
3. Discovery of Novel 4-Hydroxyquinazoline Derivatives: In Silico, In Vivo and In Vitro Studies Using Primary PARPi-Resistant Cell Lines;Molecules;2024-03-21
4. Triple Negative Breast Cancers: An Obsolete Entity?;Clinical Breast Cancer;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3